Human Health Therapeutics, National Research Council Canada, Ottawa, ON, Canada.
Methods Mol Biol. 2022;2412:255-267. doi: 10.1007/978-1-0716-1892-9_12.
Vaccine formulations utilize adjuvants to enhance the level and breadth of the immune response to a target antigen. Liposomes composed of sulfated S-lactosylarchaeol (SLA) glycolipids can induce strong humoral and cell-mediated antigen-specific immune responses to co-administered antigens in mice. This has been demonstrated with a variety of protein antigens, where the protein is either encapsulated within or simply admixed with the archaeal liposomes (archaeosomes). In this process, a dried film of SLA glycolipid is hydrated in water or antigen solution to generate a large multilamellar (ML) liposomal suspension which is then size reduced by sonication to form unilamellar vesicles (UL) with a narrower size distribution. Herein, we describe the generation of liposomes based on the archaeal-based lipid SLA for use as an adjuvant in vaccine formulations.
疫苗制剂利用佐剂来增强对目标抗原的免疫应答的水平和广度。由硫酸化 S-乳糖基胞壁酰六肽（SLA）糖脂组成的脂质体可以诱导对共施用的抗原在小鼠中产生强烈的体液和细胞介导的抗原特异性免疫应答。这已经通过各种蛋白质抗原得到证明，其中蛋白质被包裹在古生菌脂质体（古生菌体）内或简单地与古生菌脂质体混合。在此过程中，SLA 糖脂的干燥薄膜在水或抗原溶液中水合，以生成大的多层（ML）脂质体悬浮液，然后通过超声处理减小尺寸，形成具有更窄尺寸分布的单层囊泡（UL）。本文描述了基于基于古细菌的脂质 SLA 的脂质体的生成，将其用作疫苗制剂中的佐剂。
